XML 79 R40.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of the reportable segment and includes the reconciliation to consolidated net loss

The following table provides information about the Company’s one reportable segment and includes the reconciliation to consolidated net loss.

 

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Total revenues

 

$

150,042

 

 

$

87,166

 

 

$

271,505

 

 

$

162,165

 

Less:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue (excluding amortization and depreciation)

 

 

13,448

 

 

 

8,055

 

 

 

23,237

 

 

 

14,352

 

Research and development expense (excluding share-based compensation expense):

 

 

 

 

 

 

 

 

 

 

 

 

Solriamfetol

 

 

10,770

 

 

 

15,633

 

 

 

22,576

 

 

 

24,197

 

AXS-05

 

 

14,564

 

 

 

15,763

 

 

 

29,041

 

 

 

29,288

 

AXS-07

 

 

6,075

 

 

 

3,973

 

 

 

10,554

 

 

 

6,945

 

AXS-12

 

 

1,737

 

 

 

3,078

 

 

 

4,146

 

 

 

5,124

 

AXS-14

 

 

6,225

 

 

 

3,761

 

 

 

7,411

 

 

 

6,370

 

Other research and development(a)

 

 

3,229

 

 

 

2,573

 

 

 

7,198

 

 

 

5,119

 

General and administrative expense (excluding share-based compensation expense)

 

 

13,234

 

 

 

12,688

 

 

 

24,884

 

 

 

24,840

 

Selling and marketing expense (excluding share-based compensation expense)

 

 

99,376

 

 

 

74,556

 

 

 

191,664

 

 

 

145,752

 

Share based compensation expense

 

 

24,611

 

 

 

21,382

 

 

 

47,919

 

 

 

41,572

 

Loss (Gain) in fair value of contingent consideration

 

 

(8,102

)

 

 

2,160

 

 

 

(6,590

)

 

 

748

 

Interest expense, net(b)

 

 

1,834

 

 

 

1,299

 

 

 

4,265

 

 

 

2,381

 

Other segment items(c)

 

 

11,014

 

 

 

1,590

 

 

 

12,586

 

 

 

3,179

 

Segment net loss

 

 

(47,973

)

 

 

(79,345

)

 

 

(107,386

)

 

 

(147,702

)

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of net loss

 

 

 

 

 

 

 

 

 

 

 

 

Adjustments and reconciling items

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated net loss

 

 

(47,973

)

 

 

(79,345

)

 

 

(107,386

)

 

 

(147,702

)

(a)
Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs.
(b)
Interest expense, net of $1,834 for the three months ended June 30, 2025 comprises (i) consolidated interest expense of $4,086 and (ii) consolidated interest income of $2,252. Interest expense, net of $4,265 for the six months ended June 30, 2025 comprises (i) consolidated interest expense of $9,344 and (ii) consolidated interest income of $5,079. Interest expense, net of $1,299 for the three months ended June 30, 2024 comprises (i) consolidated interest expense of $5,079 and (ii) consolidated interest income of $3,780. Interest expense, net of $2,381 for the six months ended June 30, 2024 comprises (i) consolidated interest expense of $10,485 and (ii) consolidated interest income of $8,104.
(c)
Other segment items included in Segment net loss include intangible asset amortization, loss on debt extinguishment, and other miscellaneous items.